Stockscreener 앱 받기
10.94
0.18%
0.02
시간 외 거래:
10.76
-0.18
-1.65%
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - stocktwits.com
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - Kalkine
Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Sagimet Biosciences (SGMT) Surges 13.7% to $10.55 as Biotech Momentum BuildsMFI Divergence - vinanet.vn
SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Spurs 13.7% Stock RallyGrowth Acceleration Report - vinanet.vn
Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - MarketBeat
SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan
Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Form 8K Sagimet Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ) - Seeking Alpha
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat By Investing.com - Investing.com South Africa
Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst - MarketBeat
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat - Investing.com
FDA clears Sagimet Biosciences to begin Phase 3 trial of denifanstat for acne - Investing.com India
Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 - TradingView
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - Yahoo Finance
Sagimet Biosciences director George Kemble sells $201,146 in shares By Investing.com - Investing.com Canada
Sagimet Biosciences director George Kemble sells $201,146 in shares - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Given New $56.00 Price Target at Canaccord Genuity Group - MarketBeat
Why is Sagimet Biosciences stock climbing today? By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st
Why is Sagimet Biosciences stock climbing today? - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Sagimet Biosciences (SGMT) insider plans 20,206-share stock sale after option exercise - Stock Titan
0.86%
0.31%
자본화:
|
볼륨(24시간):